Despite recent modest improvements in adjusted mortality rates among hemodialysis patients, mortality rates remain above 225 per 1000 patient-years, nearly six times the rates in the general age-matched population. 1 Overall 5-year survival of hemodialysis patients remains only 31% and the mortality rate for patients on dialysis for longer than 5 years is above 250 per 1000 patient-years. 1 In the last decade, considerable emphasis has been placed on the role of abnormalities in mineral metabolism (elevated levels of calcium, phosphorus, and parathyroid hormone (PTH)) in this high rate of mortality. 2 Secondary hyperparathyroidism (SHPT) is present in a substantial percentage of hemodialysis patients and prevalence increases with increasing dialysis duration. For much of the past two decades, the primary SHPT treatments have been phosphate binders to control serum phosphorus, and intravenous (i.v.) vitamin D to suppress PTH. As i.v. vitamin D commonly increases serum calcium and phosphorus, efforts to control PTH often resulted in elevated serum calcium and phosphorus values.
Elevations in serum calcium, phosphorus, and PTH have all been associated with increased morbidity and mortality in observational studies. [3] [4] [5] [6] Observational data suggest that optimal outcomes are associated with serum calcium values in the low-normal range of 7.5-9.5 mg/dl and serum phosphorus values in the range of 3-5 mg/dl. 5 Serum PTH levels associated with optimal outcomes are less well defined and vary by specific study; however, it is difficult to show an independent effect of PTH on outcomes until PTH values are above 600 pg/ml. 6 The strength of observational data has led to many national and international patient care guidelines that recommend control of serum calcium, phosphorus, and PTH within specific ranges. The most well recognized of these sets of guidelines is the US-based National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI). The KDOQI guideline for bone and mineral disease recommends target calcium of 8.4-9.5 mg/dl, target phosphorus of 3.5-5.5 mg/dl, and target PTH of 150-300 pg/ml. alternative therapy for SHPT. The first calcimimetic, cinacalcet hydrochloride (Sensipar; Amgen, Thousand Oaks, CA, USA), was approved for clinical use in April 2004 and became commercially available in May 2004. Pivotal clinical trials were conducted in patients with persistent SHPT despite use of a standard therapy (phosphate binders and vitamin D). These trials consistently showed that adding cinacalcet reduced PTH, calcium, and phosphorus levels. 8 Extension studies and post-hoc analyses suggested that adding cinacalcet produced long-term favorable effects on these biomarkers and that patients given cinacalcet were more likely to reach target values than patients given standard therapy. 9, 10 Compelled by the observations that patients with lower serum values of calcium, phosphorus, and PTH had improved survival, we prospectively tested the hypothesis that prescribing cinacalcet to a large hemodialysis population with SHPT would be associated with improved survival.
RESULTS

Baseline characteristics
The final study population consisted of 5976 patients with cinacalcet prescriptions and 13,210 without. Detailed descriptions of patient characteristics at baseline and at first cinacalcet prescription are shown in Tables 1 and 2 . Patients with cinacalcet prescriptions were younger with longer dialysis duration, more likely to be African American, and less likely to have diabetes. In the baseline period, a higher percentage of patients with cinacalcet prescriptions had 0 hospital days and a lower percentage had 45 hospital days. Consistent with these demographic differences suggesting that patients with cinacalcet prescriptions were generally healthier, baseline cardiovascular comorbidity was also lower. Cardiovascular medication use was generally similar between patients with and without cinacalcet prescriptions; however, cinacalcet patients were less likely to receive prescriptions for calcium-containing phosphate binders and more likely to receive prescriptions for sevelamer. Baseline serum calcium, phosphorus, and PTH values were higher for cinacalcet than for non-cinacalcet patients. In particular, proportions of cinacalcet patients with severe hyperparathyroidism (PTH 4600 pg/ml), hypercalcemia (calcium 410.2 mg/dl), and hyperphosphatemia (phosphorus 48.0 mg/dl) in the baseline period were higher than proportions of non-cinacalcet patients.
Outcomes analyses: mortality
The unadjusted all-cause mortality rate for patients with cinacalcet prescriptions was significantly lower than for noncinacalcet patients (17.6 vs 23.0 deaths per 100 patient-years, respectively, hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.68-0.78, Po0.001; Table 3 ). Fully adjusted models showed an almost identical HR of 0.74 (95% CI 0.67-0.83), suggesting that demographic characteristics favoring cinacalcet patients were balanced by laboratory characteristics favoring non-cinacalcet patients (Table 4) . Unadjusted cardiovascular mortality rates were 8.1 deaths per 100 patient-years for cinacalcet patients and 10.0 for noncinacalcet patients. Models adjusted for all variables showed an HR of 0.76 (95% CI 0.66-0.86, Po0.001) for cardiovascular mortality (Table 5) .
Concomitant medication use (cardiovascular, lipid lowering) and phosphate binder use were investigated as covariates. However, there was no statistically significant association between use of these medications during the baseline period and mortality. Removing these medications from the model did not affect the parameter estimate for all-cause mortality or cardiovascular-specific mortality.
Stratified analysis
Although we detected no interactions between treatment and any factor of interest (age, sex, race, dialysis duration, diabetes, access type, body mass index (BMI), phosphorus, and PTH), and despite adjustment for multiple baseline covariates, slight differences in treatment effect between strata of covariates could occur. Thus, fully adjusted timedependent stratified analyses were conducted for all-cause mortality. The upper end of the 95% CI was o1.0 in 46 of the 59 strata presented (Figure 1 ). Stratification by severity of SHPT revealed no survival benefit for patients with PTH o150 pg/ml (HR 0.97, CI 0.74-1.26) and the largest survival benefit (HR 0.66, CI 0.53-0.83) for patients with the most severe disease (PTH 4600 pg/ml). We also conducted stratified analyses for associations with cardiovascular mortality. Trends were similar, except that CI were even wider and overlapped 1.0 more often, reflecting smaller numbers of events.
Sensitivity analyses using dialysis duration and propensity matched cohorts revealed a HR of 0.81 (CI 0.75-0.88).
DISCUSSION
This prospectively designed observational study, initiated in 2004, shows a significant survival benefit associated with prescribing cinacalcet for hemodialysis patients with evidence of SHPT and receiving i.v. vitamin D. This survival benefit was maintained after adjustment for baseline and timedependent characteristics. Sensitivity analyses designed to address the difference in dialysis duration between groups (and possible lead-time bias) modified the HR towards 1; however, significant survival benefit was maintained. In stratified analysis, the upper end of the 95% CI was o1 in most strata, supporting a consistent benefit among subgroups. Improved survival was also shown for cardiovascular mortality, consistent with the hypothesis that intervention in mineral metabolism is directly related to cardiovascular health in hemodialysis patients. That stratified analyses failed to show a survival effect in patients with PTH o150 pg/ml and the strongest effect was observed in patients with the most severe SHPT (PTH 4600 pg/ml) strongly support this hypothesis.
Because cinacalcet use has been shown to result in decrements in serum levels of calcium, phosphorus, and PTH, it is tempting to speculate that these reductions may be the proximate cause of a survival benefit. Indeed, the strength of the observational data suggesting that high levels of these minerals are associated with mortality led to the development of national and international guidelines that adopt narrow target values. 11 The KDOQI guidelines for bone and mineral disease recommend target levels of 8.4-9.5 mg/dl for calcium, 3.5-5.5 mg/dl for phosphorus, and 150-300 pg/ml for PTH. A recent report using data from a large dialysis provider (Fresenius Medical Care North America, Waltham, MA, USA) found that consistent control of mineral metabolism was associated with improved survival for hemodialysis patients, and that as patients met increasing numbers of KDOQI targets, HR of mortality were reduced. 12 In addition, sustaining each target level over time was associated with improved survival. The authors estimated that maintaining KDOQI targets for calcium, phosphorus, and PTH could reduce mortality by as much as 20%. Using data from DaVita (Denver, CO, USA), we recently reported that serum calcium, phosphorus, and PTH were significantly reduced for patients given cinacalcet prescriptions from mid 2004 to 2006, and these patients were more likely to reach KDOQI target values and less likely to experience biochemical adverse events. Characteristics collected immediately before first cinacalcet prescription or, for hospital days, in the 6 months before first cinacalcet prescription. Baseline comorbidity determined in the 6 months before first cinacalcet prescription; at least one record of medication prescription in the medication class required in the 3 months before first cinacalcet prescription to be counted as a medication exposure; baseline laboratory data determined in the 3 months before first cinacalcet prescription.
13
c Includes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other diseases of pericardium, and other diseases of the endocardium. However, it is imperative to note that no randomized clinical trial has shown that reduced serum levels of these minerals are associated with improved clinical outcome. Despite the compelling nature of our results, these data most strongly support the ongoing EVOLVE trial (Evaluation of cinacalcet HCL therapy to lower cardiovascular events; clinicaltrials.gov identifier NCT 00345839). Nephrology is currently mired in an unfortunate situation, in which observational data are used to generate clinical treatment guidelines rather than hypotheses to be tested with randomized controlled clinical trials. Such an approach has often proved to be erroneous when ultimately tested in properly conducted clinical trials. Remarkably, some members of the community go so far as to suggest that, on the basis of observational data alone, conducting randomized controlled trials is precluded on ethical grounds. We must resist adopting this approach.
As with all observational reports, the current study has several limitations. Chief among these is the possibility that residual confounding by indication might be responsible for our findings. However, this analysis has several strengths that distinguish it from previous observational reports on outcome in this clinical arena. Merging data from DaVita with data from the United States Renal Data System (USRDS) allowed us to characterize and adjust for comorbidity and hospitalization at study entry and to update these factors at cinacalcet initiation. Furthermore, use of USRDS data allowed us to more fully identify mortality events. Previous reports using only large dialysis chain data are limited in this regard because of individual patients leaving a particular provider or changing health insurance. Using USRDS data, we identified approximately 3600 more deaths than we would have identified using only DaVita-provided mortality information. Our analysis mimicked an intent-totreat trial design by forcing patients who received cinacalcet prescriptions to stay in the exposed arm. Any misclassification bias that might have occurred with this approach would serve only to minimize the likelihood of finding an independent effect. Uniquely, compared with previous work, our analyses included only patients who had received i.v. vitamin D, the main treatment for SHPT, before cinacalcet availability. Previous reports comparing outcomes among exposed and unexposed patient populations have all been susceptible to confounding by indication, in that patients Includes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other disease of pericardium, and other diseases of the endocardium. who never received the medication of interest were different from those who did, in ways that cannot be adjusted for in routine analyses. Because of previous observational reports of survival benefit for patients exposed to i.v. vitamin D, we believed that eliminating this feature as a potential confounder was important. Vitamin D use may have differed modestly after exposure to cinacalcet; however, because this event would be in the causal pathway of potential clinical benefit, we did not find it reasonable to adjust for vitamin D use in our model. In addition, we previously reported that changes in vitamin D dose are very modest for patients in this population with cinacalcet prescriptions. 13 It is noteworthy that we did not investigate potential mechanisms of action as to the reason cinacalcet prescription was associated with survival benefit, and any hypotheses in this regard must be considered speculative.
In this prospectively designed observational cohort study, we found that prescription of cinacalcet to hemodialysis patients with SHPT, who have received i.v. vitamin D, was associated with significant reductions in all-cause and cardiovascular mortality. We must emphasize, however, that these results are observational and cannot establish a causeand-effect relationship. These data do not definitively establish a survival effect of cinacalcet, and we caution against interpreting these data in any way other than supporting the hypothesis that intervention with cinacalcet and the resultant favorable effect on parameters of mineral metabolism may be in the clinical pathway for cardiovascular outcomes. Definitive evidence of actual clinical benefit will be ascertained in the ongoing EVOLVE clinical trial. However, our results provide compelling data, indicating that interventions to reduce calcium, phosphorus, and PTH levels are associated with meaningful patient outcomes. Includes ill-defined complication of heart disease, tachycardia, palpitations, murmurs, acute pericarditis, acute and subacute endocarditis, other disease of pericardium, and other diseases of the endocardium.
Figure 1 | Hazard ratios and 95% confidence intervals (CI) for mortality associated with cinacalcet prescription stratified by patient characteristics. Each row reflects a multivariable adjusted model including the covariates in our final model (see Table 4 ). The number of patients in each group (patients with and without cinacalcet prescriptions) within each stratum is represented by n. Circles represent point estimates and horizontal lines 95% CI. The referent group for each analysis is the group without cinacalcet prescriptions. ASHD, atherosclerotic heart disease; BMI, body mass index; CHF, congestive heart failure; CVA, cerebrovascular accident/transient ischemic attack; DM, diabetes; GN, glomerulonephritis; HTN, hypertension; PTH, parathyroid hormone; PVD, peripheral vascular disease. 
Home medication determinations
The DaVita home medication files contain detailed medication information. Drug-specific files were created for cinacalcet by searching for its generic and trade name. Each file was reviewed by study personnel to verify the drug name, dose, and administration frequency. Final drug-specific sequence files contained unique dates for each prescription start, stop, and dosage change. Validity of actual cinacalcet use was confirmed by biochemical evidence of reductions in serum calcium, phosphorus, and PTH in the month immediately following cinacalcet initiation.
The study cohort was examined for additional concomitant medications often prescribed for hemodialysis patients (e.g., phosphate binders). At least one record of medication prescription within the medication class was required during the 3-month baseline period (August-October 2004) to count as a medication exposure (Table 2) .
Cinacalcet exposure
Cinacalcet exposure was defined as a dichotomous variable on the basis of the presence (1, yes) or absence (0, no) of a cinacalcet prescription during the study period, and was used as a timedependent variable on the basis of first cinacalcet prescription date. Follow-up time for all patients started on 1 November 2004. Time before first cinacalcet prescription was attributed to the noncinacalcet treatment group. Treatment status changed with first cinacalcet prescription. Once designated as cinacalcet patients, patients were considered to be cinacalcet patients until the end of the study period.
Statistical methods
A time-dependent Cox proportional hazards regression model was used to assess all-cause and cardiovascular mortality. Baseline demographic, comorbidity, hospital days, vascular access, and laboratory information, and phosphate binder and cardiovascular medication use were used as covariates.
Cinacalcet prescription was treated as a time-dependent variable. Age, dialysis duration, BMI, most recent vascular access type, hospital days in the previous 6 months, and most recent laboratory values within 3 months of cinacalcet start were updated on cinacalcet initiation. Vascular access type and laboratory values were also updated quarterly in the follow-up period for both patient groups, except that calcium, phosphorus, and PTH were not updated quarterly as these biochemical markers may be in the causal pathway for any effect that cinacalcet may have on mortality.
Unadjusted and adjusted analyses were performed. Models for adjusted analyses were adjusted for the factors noted above. Homogeneity of treatment effect across levels of these factors was assessed through additional models, including an interaction term of treatment with one of the factors of interest (age, sex, race, dialysis duration, diabetes, access type, BMI, phosphorus, and PTH), and main effects of all variables. The final model included significant (Po0.05) interaction terms and all main effects. As no interactions were detected, no interaction terms were included in the final model. Patients were followed from 1 November 2004 to death. Censoring was applied for modality change (including kidney transplant), withdrawal from dialysis, loss to follow-up (lack of CMS ESRD dialysis claims), or end of 2006.
To address the possibility of lead-time bias that might be created by difference in the dialysis duration between groups, a sensitivity analysis was conducted. Groups based on dialysis duration (monthly through month 120, yearly from months 121 to 168, and a single cohort after month 168) were created. A propensity score was developed to predict factors associated with cinacalcet prescription. Factors important in this model included BMI, age, diabetes, duration of SHPT, dialysis duration, sex, race, hospital days in the preceding 6 months, albumin, calcium, phosphorus, and PTH. This propensity score was divided by intervals that corresponded to approximately 0.25 of an s.d. of the score. Cross-classifying the 24 propensity levels and the 126 dialysis duration categories yielded 2435 cohorts of cinacalcet and non-cinacalcet patients. Cinacalcet patients were matched with non-cinacalcet patients by baseline dialysis duration and propensity score. We subsequently performed the same Cox regression model with Anderson-Gill approach stratifying by matching groups.
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